UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                           --------------------------


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


         Date of report (Date of earliest event reported) April 3, 2007




                                Neurologix, Inc.
                                ----------------
               (Exact Name of Registrant as Specified in Charter)

                        Commission File Number: 000-13347
                                                ---------

             Delaware                                    06-1582875
             --------                                    ----------
   (State or other Jurisdiction                       (I.R.S. Employer
         of Incorporation)                           Identification No.)


                  One Bridge Plaza, Fort Lee, New Jersey 07024
                  --------------------------------------------
                    (Address of Principal Executive Offices)
                                   (Zip Code)


                                 (201) 592-6451
                                 --------------
              (Registrant's telephone number, including area code)


                                 Not Applicable
                                 --------------
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))





Item 2.02    Results of Operations and Financial Condition.

     On April 3, 2007, Neurologix, Inc. issued a press release announcing its
earnings for the year ended December 31, 2006. A copy of the press release is
furnished herewith as Exhibit 99.1.

     The information, including the exhibit attached hereto, in this Current
Report is being furnished and shall not be deemed "filed" for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any registration statement or
other document pursuant to the Securities Act of 1933, as amended, except as
otherwise expressly stated in such filing.


Item 9.01.   Financial Statements and Exhibits.

       (d)     Exhibits

         99.1    Press Release issued by Neurologix, Inc. on April 3, 2007.






                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date: April 3, 2007


                                           NEUROLOGIX, INC.

                                           By: /s/  Marc L. Panoff
                                               ---------------------------------
                                               Marc L. Panoff
                                               Chief Financial Officer,
                                               Secretary and Treasurer